John Rathbone1, Hannele Variend, Hetal Mehta. 1. Cochrane Schizophrenia Group, University of Nottingham, Duncan MacMillan House, Portchester Road, Nottingham, UK, NG3 6AA. John.Rathbone@nottingham.ac.uk
Abstract
BACKGROUND: Many people with schizophrenia use cannabis and its effects on the illness are unclear. OBJECTIVES: To evaluate the effects of cannabis use on people with schizophrenia and schizophrenia-like illnesses. SEARCH STRATEGY: We searched the Cochrane Schizophrenia Group Trials Register (April 2007) which is based on regular searches of BIOSIS, CENTRAL, CINAHL, EMBASE, MEDLINE and PsycINFO. SELECTION CRITERIA: We included all randomised trials involving cannabinoids and people with schizophrenia or schizophrenia-like illnesses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis, based on a fixed effects model. We calculated the numbers needed to treat/harm (NNT/NNH). For continuous data, we calculated weighted mean differences (WMD) again based on a fixed effects model. MAIN RESULTS: We identified one randomised trial. No significant differences were found between the Cannabis and Psychosis Therapy (CAP) intervention group and the Psychoeducaton (PE) intervention for use of cannabis at three months assessment (n=47, RR 1.04 CI 0.6 to 1.7). BPRS-extended scale scores at three months assessment (n=47, WMD -3.60 CI -12.8 to 5.6) and nine months assessment (n=47, WMD 0.80 CI -7.5 to 9.1) were non-significant between CAP and PE. We found no significant improvement in social functioning in the CAP group compared with PE (at 3 months, n=47, WMD -0.80 CI -10 to 8.4) and (at 9 months, n=47, WMD -4.70 CI -14.5 to 5.1). AUTHORS' CONCLUSIONS: At present, there is insufficient evidence to support or refute the use of cannabis/cannabinoid compounds for people suffering with schizophrenia. This review highlights the need for well designed, conducted and reported clinical trials to address the potential effects of cannabis based compounds for people with schizophrenia.
BACKGROUND: Many people with schizophrenia use cannabis and its effects on the illness are unclear. OBJECTIVES: To evaluate the effects of cannabis use on people with schizophrenia and schizophrenia-like illnesses. SEARCH STRATEGY: We searched the Cochrane Schizophrenia Group Trials Register (April 2007) which is based on regular searches of BIOSIS, CENTRAL, CINAHL, EMBASE, MEDLINE and PsycINFO. SELECTION CRITERIA: We included all randomised trials involving cannabinoids and people with schizophrenia or schizophrenia-like illnesses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis, based on a fixed effects model. We calculated the numbers needed to treat/harm (NNT/NNH). For continuous data, we calculated weighted mean differences (WMD) again based on a fixed effects model. MAIN RESULTS: We identified one randomised trial. No significant differences were found between the Cannabis and Psychosis Therapy (CAP) intervention group and the Psychoeducaton (PE) intervention for use of cannabis at three months assessment (n=47, RR 1.04 CI 0.6 to 1.7). BPRS-extended scale scores at three months assessment (n=47, WMD -3.60 CI -12.8 to 5.6) and nine months assessment (n=47, WMD 0.80 CI -7.5 to 9.1) were non-significant between CAP and PE. We found no significant improvement in social functioning in the CAP group compared with PE (at 3 months, n=47, WMD -0.80 CI -10 to 8.4) and (at 9 months, n=47, WMD -4.70 CI -14.5 to 5.1). AUTHORS' CONCLUSIONS: At present, there is insufficient evidence to support or refute the use of cannabis/cannabinoid compounds for people suffering with schizophrenia. This review highlights the need for well designed, conducted and reported clinical trials to address the potential effects of cannabis based compounds for people with schizophrenia.
Authors: Deepak Cyril D'Souza; Walid Michel Abi-Saab; Steven Madonick; Kimberlee Forselius-Bielen; Anne Doersch; Gabriel Braley; Ralitza Gueorguieva; Thomas B Cooper; John Harrison Krystal Journal: Biol Psychiatry Date: 2005-03-15 Impact factor: 13.382
Authors: Mayumi Okuda; Deborah S Hasin; Mark Olfson; Sharaf S Khan; Edward V Nunes; Ivan Montoya; Shang-Min Liu; Bridget F Grant; Carlos Blanco Journal: Drug Alcohol Depend Date: 2010-05-26 Impact factor: 4.492
Authors: Berend Malchow; Alkomiet Hasan; Thomas Schneider-Axmann; Alexander Jatzko; Oliver Gruber; Andrea Schmitt; Peter Falkai; Thomas Wobrock Journal: Eur Arch Psychiatry Clin Neurosci Date: 2013-10-02 Impact factor: 5.270